Antonio Bastardo’s career was twice shadowed by performance-enhancing-drug suspensions. In August 2013, while he was a productive Philadelphia Phillies reliever with a 3–2 record and a 2.32 ERA, Major League Baseball suspended him for 50 games as part of the Biogenesis scandal. The investigation centered on the Biogenesis of America clinic in Miami and its operator, Anthony Bosch, whose records implicated numerous prominent baseball players in alleged performance-enhancing-drug use. Bastardo was one of the players disciplined by MLB, meaning his promising season ended immediately and he was barred from the remainder of the campaign. The suspension was especially damaging to his reputation because it came during a season in which he had been regarded as one of Philadelphia’s dependable bullpen arms, rather than after an obvious decline in performance.
Five years later, the scandal became more severe. On July 20, 2018, Bastardo received a 140-game suspension after testing positive for stanozolol, an anabolic steroid associated with strength enhancement and banned under MLB’s performance-enhancing-drug policy. The second suspension effectively marked the collapse of his professional career: he had already been released by Pittsburgh in 2017, failed to make Arizona’s roster in 2018, and did not return to the majors. His case stands out not merely as a single connection to a major baseball doping investigation, but as a rare repeat-PED violation that transformed a veteran reliever’s résumé into a cautionary example of how doping sanctions can permanently overshadow legitimate on-field accomplishments.
Follow the sources
Status and citations are supplied by the archive. AI concept art is an interpretation, not historical evidence.
AI concept artwork · not archival photography